血小板减少症：阿哌沙班的一种可能副作用。
Thrombocytopenia: A possible side effect of apixaban.
作者信息
Sadaka Farid
机构信息
Mercy Hospital St Louis St. Louis University St. Louis Missouri.
出版信息
Clin Case Rep. 2019 Nov 21;7(12):2543-2544. doi: 10.1002/ccr3.2532. eCollection 2019 Dec.
Abstract
Apixaban is becoming more frequently prescribed for stroke prevention in patients with atrial fibrillation, and even rare side effects such as thrombocytopenia should be considered and monitored closely.
摘要
阿哌沙班越来越多地被用于预防心房颤动患者的中风，即使是血小板减少症等罕见的副作用也应予以考虑并密切监测。
相似文献
1
Thrombocytopenia: A possible side effect of apixaban.血小板减少症：阿哌沙班的一种可能副作用。
Clin Case Rep. 2019 Nov 21;7(12):2543-2544. doi: 10.1002/ccr3.2532. eCollection 2019 Dec.
2
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
3
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.法国非瓣膜性心房颤动患者中阿哌沙班预防卒中和全身性栓塞：PAROS 横断面研究常规临床实践。
Arch Cardiovasc Dis. 2019 Jun-Jul;112(6-7):400-409. doi: 10.1016/j.acvd.2019.02.003. Epub 2019 Apr 20.
4
Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.口服抗凝药物在心房颤动患者中的用药模式：韩国全国范围内基于人群的研究。
Adv Ther. 2022 Jul;39(7):3112-3130. doi: 10.1007/s12325-022-02151-z. Epub 2022 May 7.
5
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
6
7
Selecting the right anticoagulant for stroke prevention in atrial fibrillation.选择合适的抗凝药物预防房颤相关性卒中。
Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4499-4505. doi: 10.26355/eurrev_202107_26241.
8
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界中阿哌沙班在房颤卒中预防中的应用：系统评价和荟萃分析。
Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.
9
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.阿哌沙班与其他新型口服抗凝药预防心房颤动卒中的成本效益比较。
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.
10
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.非瓣膜性心房颤动患者口服抗凝药的安全性和有效性比较：NAXOS 研究。
Stroke. 2020 Jul;51(7):2066-2075. doi: 10.1161/STROKEAHA.120.028825. Epub 2020 Jun 16.
引用本文的文献
1
Anticoagulants versus Left Atrial Appendage Occlusion in Patients with Atrial Fibrillation and Co-Morbid Thrombocytopenia.心房颤动合并血小板减少症患者中抗凝剂与左心耳封堵术的比较
J Clin Med. 2023 Dec 12;12(24):7637. doi: 10.3390/jcm12247637.
2
Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin.直接口服抗凝药和低分子量肝素所致血小板减少症
Cureus. 2021 Oct 13;13(10):e18757. doi: 10.7759/cureus.18757. eCollection 2021 Oct.
3
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.2021年欧洲心律协会心房颤动患者使用非维生素K拮抗剂口服抗凝药实用指南。
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
本文引用的文献
1
Case report: apixaban-induced thrombocytopenia.病例报告：阿哌沙班引起的血小板减少症。
Clin Case Rep. 2017 Feb 1;5(3):268-269. doi: 10.1002/ccr3.809. eCollection 2017 Mar.
2
Novel oral anticoagulants for heparin-induced thrombocytopenia.用于肝素诱导的血小板减少症的新型口服抗凝剂。
J Thromb Thrombolysis. 2016 Aug;42(2):172-8. doi: 10.1007/s11239-016-1365-0.
3
Novel oral anticoagulants in cardiovascular disease.心血管疾病中的新型口服抗凝剂。
J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):34-44. doi: 10.1177/1074248413501392. Epub 2013 Sep 13.
4
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
5
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.药物诱导的血小板减少症：发病机制、评估和管理。
Hematology Am Soc Hematol Educ Program. 2009:153-8. doi: 10.1182/asheducation-2009.1.153.
6
Management of thrombocytopenia in bone marrow failure: a review.骨髓衰竭中血小板减少症的管理：综述
J Palliat Med. 2007 Feb;10(1):236-44. doi: 10.1089/jpm.2006.0126.
Zotero 插件